
# RealRate

### PHARMACEUTICAL 2021

# Mallinckrodt plc Rank 150 of 409







### PHARMACEUTICAL 2021

## Mallinckrodt plc Rank 150 of 409



The relative strengths and weaknesses of Mallinckrodt plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mallinckrodt plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Mallinckrodt plc is the variable Assets, Current, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 302% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,304,300
Cost of Goods Sold	1,544,000
Intangible Assets	6,184,500
Liabilities, Current	4,118,700
Liabilities, Non-Current	109,800
Other Assets	393,500
Other Compr. Net Income	-1,700
Other Expenses	1,030,100
Other Liabilities	4,467,700
Other Net Income	55,000
Property and Equipment	833,100
Research and Development	290,800
Revenues	2,213,400
Selling, General and Administrative Expense	884,100

Output Variable	Value in 1000 USD
Assets	9,715,400
Liabilities	8,696,200
Expenses	3,749,000
Stockholders Equity	1,019,200
Net Income	-1,480,600
Comprehensive Net Income	-1,481,450
Economic Capital Ratio	-53%